Paperpal Prime Logo

Journal of Biopharmaceutical Statistics : Impact Factor & More

eISSN: 1520-5711pISSN: 1054-3406

Key Metrics

CiteScore
1.8
H-Index
53
Impact Factor
< 5
SJR
Q2Pharmacology
SNIP
0.98
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on Journal of Biopharmaceutical Statistics

Journal of Biopharmaceutical Statistics Journal Specifications

Overview
Publisher TAYLOR & FRANCIS INC
Language English
Frequency Bi-monthly
General Details
LanguageEnglish
FrequencyBi-monthly
Publication Start Year1991
Publisher URLVisit website
Website URLVisit website
View less

Planning to publish in Journal of Biopharmaceutical Statistics ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in Journal of Biopharmaceutical Statistics

Handling missing data using multiple imputation in hybrid control clinical trials with modified power prior
  • 8 Aug 2026
  • Journal of Biopharmaceutical Statistics
Randomization-based covariance analysis for hypothesis testing of treatment comparisons based on restricted mean survival time with categorized time-to-event data
  • 7 Aug 2026
  • Journal of Biopharmaceutical Statistics
A phase II, seamless single-arm to two-arm Bayesian design for a time-to-event endpoint
  • 1 Aug 2026
  • Journal of Biopharmaceutical Statistics
Balancing sample size and accuracy of dose selection in phase 1 oncology trials – designs tiered by cohort size and maximum number of patients treated per dose
  • 27 Jul 2026
  • Journal of Biopharmaceutical Statistics
Industrialization of Bayesian decision-making for proof-of-commercial-concept study designs
  • 25 Jul 2026
  • Journal of Biopharmaceutical Statistics
Why the minimum effective dose is unidentifiable – and how a DOR→OOD standard delivers label-ready dosing in oncology
  • 25 Jul 2026
  • Journal of Biopharmaceutical Statistics
Handling missing data using multiple imputation in hybrid control clinical trials with modified power prior
  • 8 Aug 2026
  • Journal of Biopharmaceutical Statistics
Randomization-based covariance analysis for hypothesis testing of treatment comparisons based on restricted mean survival time with categorized time-to-event data
  • 7 Aug 2026
  • Journal of Biopharmaceutical Statistics
A phase II, seamless single-arm to two-arm Bayesian design for a time-to-event endpoint
  • 1 Aug 2026
  • Journal of Biopharmaceutical Statistics
Balancing sample size and accuracy of dose selection in phase 1 oncology trials – designs tiered by cohort size and maximum number of patients treated per dose
  • 27 Jul 2026
  • Journal of Biopharmaceutical Statistics
Industrialization of Bayesian decision-making for proof-of-commercial-concept study designs
  • 25 Jul 2026
  • Journal of Biopharmaceutical Statistics
Why the minimum effective dose is unidentifiable – and how a DOR→OOD standard delivers label-ready dosing in oncology
  • 25 Jul 2026
  • Journal of Biopharmaceutical Statistics

FAQs on Journal of Biopharmaceutical Statistics